Kilitch Drugs (India) (KDIL) has planned to focus on African markets with a state-of-the-art Cephalosporin injectable plant near Adis Ababa - capital city of Ethiopia. The unit will have a capacity of 20 million vials and commence operations in FY19-20. Besides vials, the plant will also produce tablets, capsules, dry syrup, etc.
By 2020, KDIL plans to register more than 500 products in the African markets, which is the next bastion for growth.
Kilitch Drugs (India) is an India-based company engaged in pharmaceutical business. The Company’s services range from manufacturing to marketing a host of formulations in all dosage forms, such as solid, liquid and parenteral forms.
